Archives
-
ATS-9R Workflow for Adipose Gene Silencing
2026-09-20
ATS-9R combines Prohibitin recognition with a nona-arginine nucleic-acid delivery domain to concentrate gene modulation in white adipose tissue. This practical workflow covers complex formation, adipocyte and macrophage assays, in vivo dosing logic, and troubleshooting for obesity-associated inflammation and metabolic disease research.
-
Dibutyryl-cAMP, sodium salt: Reliable Assays
2026-09-19
Learn how Dibutyryl-cAMP, sodium salt (SKU B9001) can improve the interpretability of cAMP perturbation experiments involving viability, proliferation, cytotoxicity, and differentiation. This scenario-based guide covers mechanism, solvent compatibility, protocol controls, data interpretation, and practical supplier selection.
-
Separating Growth Inhibition from Cancer Cell Death
2026-09-18
Hannah Schwartz’s dissertation shows that relative viability and fractional viability are not interchangeable measures of anticancer drug response. By separating proliferative inhibition from cell killing and considering their timing, the work offers a clearer framework for interpreting in vitro efficacy data and designing translational experiments.
-
Biomimetic IL-12 mRNA Nanoparticles for GBM
2026-09-18
Zhao et al. developed cRGD-modified cancer-cell-membrane-coated calcium carbonate nanoparticles for ultrasound-triggered delivery of IL-12 mRNA in glioblastoma. The platform combines brain-tumor targeting, ultrasound-induced necroptosis, and local cytokine expression, offering a mechanistically integrated approach to overcoming the blood–brain barrier and reshaping the glioblastoma immune microenvironment.
-
Minocycline and Early Implant Wound Healing
2026-09-17
This randomized clinical and in vitro study identifies a concentration-dependent effect of minocycline on human gingival fibroblasts and early peri-implant healing. Its translational design links fibroblast proliferation, migration, collagen preservation, inflammatory markers, and early bacterial colonization, while also highlighting the need for dose-sensitive interpretation.
-
PKH26 Red Fluorescent Cell Linker Kit Guide
2026-09-17
The PKH26 Red Fluorescent Cell Linker Kit provides red fluorescent labeling of cell-membrane lipid regions for cell tracing and proliferation-oriented assays. It is intended for membrane-associated labeling in vitro or in vivo, not for intracellular targets, non-membrane antigens, or direct measurement of gene or protein expression.
-
EZ Cap™ OVA mRNA: A Translational Benchmark
2026-09-16
A translational framework for using defined Ovalbumin mRNA to disentangle antigen biology, intracellular delivery, protein expression enhancement, and inflammation across immune research and vaccine development workflows.
-
GPC3-HSP70 mRNA Nanovaccine for HCC
2026-09-16
Wang and colleagues developed an mRNA nanovaccine that combines tandem GPC3-derived CTL epitopes, HSP70-mediated immune stimulation, and SP94-directed tumor delivery. In preclinical testing, the formulation increased antigen-specific T-cell responses, while combination with anti-PD-L1 therapy produced stronger antitumor activity than either approach alone.
-
(-)-Norepinephrine (+)-bitartrate Workflows
2026-09-15
Build reproducible adrenergic assays with (-)-Norepinephrine (+)-bitartrate, from receptor-binding measurements to cardiovascular phenotype studies. This guide combines formulation control, open-tubular capillary electrochromatography, and troubleshooting strategies for more interpretable signaling and cardiomyopathy research.
-
HyperScribe All in One mRNA Synthesis Kit: Assay Design
2026-09-15
Explore how the HyperScribe All in One mRNA Synthesis Kit Plus 1 integrates ARCA capping, 5mCTP, ψUTP, T7 transcription, and poly(A) tailing. This article connects RNA chemistry with immune-monitoring decisions in next-generation vaccine research.
-
Self-Amplifying RNA for Dose-Sparing Influenza Vaccines
2026-09-14
This study shows that self-amplifying RNA can address the weak influenza B immunogenicity observed with conventional mRNA vaccination in mice. A low-dose trivalent self-amplifying RNA vaccine produced durable antibody responses and complete protection against influenza B challenge, supporting platform-specific optimization rather than assuming that all RNA vaccine formats perform equivalently.
-
Bsa I (RNase-free): Workflow and QC Guide
2026-09-13
Bsa I (RNase-free), SKU K1095, provides sequence-directed type IIS DNA cleavage for gene cloning, DNA manipulation, and other molecular biology research workflows where RNA contamination should be minimized. It is intended for scientific research only, not diagnostic, clinical, or medical use, and reaction conditions should be confirmed against the current product instructions.
-
Geneticin (G418 Sulfate) for Stable Cell Workflows
2026-09-12
Geneticin, also called G418 Sulfate, combines dependable selection of neomycin-resistant cells with experimentally useful translation inhibition. This guide connects practical kill-curve design and stable cell-line development with prostate cancer signaling assays and carefully controlled Dengue virus research.
-
Capecitabine in Patient-Matched Assembloids
2026-09-11
Capecitabine enables a practical test of fluoropyrimidine response in tumor-only organoids versus patient-matched tumor–stroma assembloids. This workflow emphasizes enzymatic activation, stromal modulation, fresh-solution handling, and mechanistic apoptosis readouts rather than relying on viability alone.
-
EZ Cap™ OVA mRNA Workflow for Low-Inflammation Delivery
2026-09-11
Use EZ Cap™ OVA mRNA as a standardized antigen-expression input for immune response immunogen studies, carrier benchmarking, and vaccine development research. Its Cap 1 structure and poly(A) tail help researchers distinguish delivery performance from variability in antigen production, including in low-inflammation lipid nanoparticle workflows.